Paroxysmal supraventricular tachycardia (later referred to as supraventricular tachycardia, abbreviated as PSVT) is a relatively common clinical tachyarrhythmia, with an incidence of about 1-3/1000 people, and the common symptom is panic, with a sudden onset and termination, lasting from a few seconds to several hours. Most patients have panic attacks caused by tachycardia that affect their life and work without major risks. Some patients have episodes of rapid heart rate, sometimes leading to hypotension, dizziness, blackness in front of the eyes, and even syncope. Patients with coronary artery disease may lead to myocardial ischemic attacks causing chest pain, which can be dangerous. The diagnosis of supraventricular tachycardia relies on an electrocardiogram (ECG), which can be shown to a cardiovascular specialist during an attack. However, many patients do not have access to an ECG immediately after an episode of supraventricular tachycardia, and by the time they arrive at the hospital, the tachycardia has already terminated, making the diagnosis difficult to establish. Therefore, patients with similar symptoms should first count their pulse or listen to their heart rate at the onset, which usually shows a significant increase in pulse or heart rate, between 130-250 beats per minute, with a regular rhythm, and sometimes it is difficult to count when the heart rate is too fast, so patients should usually train themselves to take a pulse or listen to their heartbeat. If you have an electronic blood pressure monitor with heart rate counting at hand, you can generally get a more accurate heart rate. A small percentage of patients show signs of pre-excitation syndrome on the ECG in the absence of an attack. The treatment of supraventricular tachycardia includes three aspects: termination of treatment in the acute phase, prevention of attacks in the chronic phase and catheter ablation for eradication. It is worth reminding that a common mistake among the patients we have contacted is the choice of coronary artery-dilating drugs such as rapid-acting cardiac pills or muscovado heart pills as self-help medication at the onset. Since the rapid heart rate during the onset of supraventricular tachycardia may cause hypotension, the blood pressure is further reduced with the use of vasodilators, which may lead to aggravation of symptoms or even cause danger. Therefore patients without clear coronary artery disease, or patients without evidence of myocardial ischemia such as chest pain or tightness during an attack, are not recommended to use the above-mentioned coronary-dilating drugs. Experienced patients can usually consult a medical professional for vagus nerve stimulation maneuvers and use partial energy transduction rhythm after an attack. Most patients choose to go to the hospital and be diverted with intravenous antiarrhythmic drugs (patients are advised to keep their emergency medical records for the physician’s reference when selecting drugs), and those who are ineffective may consider esophageal pacing therapy, and those with severe symptoms may require electrical cardioversion. Prevention of the chronic phase is mainly by oral antiarrhythmic drugs, the efficacy of almost all of which is not very certain at present. Catheter ablation is a new technique that emerged after the 1990s, in which a catheter is inserted into the heart through a punctured vessel to locate the key site of the supraventricular tachycardia (what we call the “target”) and deliver radiofrequency energy to remove it. After more than 20 years of development, it has matured in the field of various tachyarrhythmias, especially in the treatment of supraventricular tachycardia, with success rates approaching 100% and recurrence rates as low as 1-2% in established electrophysiology centers. Catheter ablation is a minimally invasive procedure, and the patient can be out of bed 6-8 hours after the procedure, and is usually discharged the next day. Considering the advantages of catheter ablation such as minimally invasive, safe, almost painless, high success rate and low recurrence rate (radical), the current guidelines have specified it as one of the preferred treatment measures for supraventricular tachycardia.